Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients

Transplantation

Volumn 101, Issue 9, 2017, Pages 2079-2082

  Radhakrishnan, Kavita ^a   Chi, Aileen ^b   Quan, David J ^b   Roberts, John P ^b   Terrault, Norah A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE ANALOG; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA; ADVERSE EFFECTS; BLOOD; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; END STAGE LIVER DISEASE; GENETICS; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 85017622308     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001786     Document Type: Article

References (27)

1. United Network for Organ Sharing. United network for organ sharing website. www.unos.org. Published 2015.
2. Fox AN, Terrault NA. The option ofHBIG-free prophylaxis against recurrent HBV. J Hepatol. 2012;56:1189-1197.
3. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104-111.
4. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13: 619-626.
5. Terrault N, Roche B, Samuel D.Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl. 2005;11:716-732.
6. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue( s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: A systematic review. Am J Transplant. 2013;13:353-362.
7. Teperman LW, Poordad F, Bzowej N, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19:594-601.
8. Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int. 2014;27:1022-1028.
9. IshigamiM, Ogura Y, Hirooka Y, et al. Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol. 2015;21:10290-10298.
10. Roche B, Roque-Afonso AM, Nevens F, et al. Rational basis for optimizing short and long-termhepatitis B virus prophylaxis post liver transplantation: Role of hepatitis B immune globulin. Transplantation. 2015;99:1321-1334.
11. Fung J,Wong TC,Chok K, et al. Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years. [published online March 31, 2017]. Hepatology. doi: 10.1002/hep.29191.
12. Couto CA, Bittencourt PL, Farias AQ, et al. Human polyclonal antihepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B. Rev Inst Med Trop Sao Paulo. 2001;43:335-337.
13. Farges O, Saliba F, Farhamant H, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: Possible influence of alcohol and polyclonal immunoglobulins. Hepatology. 1996;23: 240-248.
14. Wong SY, Levitsky J. Chronic rejection related to hepatitis B immunoglobulin discontinuation in a liver transplant recipient. Transpl Int. 2011;24: E104-e106.
15. Lee EC, Kim SH, Lee SD, et al. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol. 2016;22:3803-3812.
16. Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587-593.
17. Fung J, Cheung C, CHan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212-1219.
18. Lenci I, P.D., Milana M, Santopaolo F, et al. Long-term complete prophylaxis withdrawal in liver-transplanted patients for HBV-related cirrhosis is safe and frequently associated with spontaneous ANTI-Hbs seroconversion. Hepatology. 2015;62(S1).
19. Coffin CS, Mulrooney-Cousins PM, Peters MG, et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18:415-423.
20. Mason A, Wick M,White H, et al. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology. 1993;18: 781-789.
21. Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl. 2009;15:1525-1534.
22. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134:1890-1899; quiz 2155.
23. Shim J, Kim BH, Kim NH, et al. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2005;20:746-751.
24. Mahtab MA, Akbar SM, Rahman S. Hepatitis B surface antigen-negative, but HBV DNA-positive patients in Bangladesh. Bangladesh Med Res Counc Bull. 2012;38:104-107.
25. Chen L, Zhao H, Yang X, et al. HBsAg-negative hepatitis B virus infection and hepatocellular carcinoma. Discov Med. 2014;18:189-193.
26. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60:723-731.
27. Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59:1726-1737.